Zobrazeno 1 - 10
of 72
pro vyhledávání: '"Jindrich Finek"'
Autor:
Ondřej Fiala, Michaela Tkadlecová, Kristýna Pivovarčíková, Jan Baxa, Petr Stránský, Dominika Šiková, Milan Hora, Jindřich Fínek
Publikováno v:
Case Reports in Oncology, Vol 17, Iss 1, Pp 921-927 (2024)
Introduction: Combined immuno-oncology (IO) regimens are the cornerstone of the current front-line systemic therapy for metastatic renal cell carcinoma (mRCC). Despite the fact that combined IO regimens show high efficacy, they are often accompanied
Externí odkaz:
https://doaj.org/article/a58094ae305241c5b82579073dce00d2
Autor:
Ondřej Fiala, Petr Hošek, Hana Korunková, Milan Hora, Jiří Kolář, Ondřej Šorejs, Ondřej Topolčan, Jan Filipovský, Václav Liška, Matteo Santoni, Sebastiano Buti, Jindřich Fínek
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Background The introduction of novel hormonal therapies represented by enzalutamide (ENZ) and abiraterone acetate (ABI) has reached a great progress in the treatment of metastatic castration‐resistant prostate cancer (mCRPC). The majority
Externí odkaz:
https://doaj.org/article/5f8e63dc27574f2fb1ca38cbf6ec024b
Autor:
Roger von Moos, Jean-Jacques Body, Oliver Guenther, Evangelos Terpos, Yves Pascal Acklin, Jindrich Finek, João Pereira, Nikos Maniadakis, Guy Hechmati, Susan Talbot, Harm Sleeboom
Publikováno v:
Journal of Bone Oncology, Vol 10, Iss C, Pp 49-56 (2018)
Background: Bone metastases and lytic lesions due to multiple myeloma are common in advanced cancer and can lead to debilitating complications (skeletal-related events [SREs]), including requirement for radiation to bone. Despite the high frequency o
Externí odkaz:
https://doaj.org/article/eb7c23d709e04c5093ed19529f04fb48
Autor:
Radek Lakomy, Alexandr Poprach, Zbynek Bortlicek, Bohuslav Melichar, Renata Chloupkova, Rostislav Vyzula, Milada Zemanova, Katerina Kopeckova, Marek Svoboda, Ondrej Slaby, Igor Kiss, Hana Studentova, Jaroslav Juracek, Ondrej Fiala, Jindrich Kopecky, Jindrich Finek, Ladislav Dusek, Karel Hejduk, Tomas Buchler
Publikováno v:
BMC Cancer, Vol 17, Iss 1, Pp 1-8 (2017)
Abstract Background It is well known that patient characteristics and survival outcomes in randomized trials may not necessarily be similar to those in real-life clinical practice. The aim of the present study was to analyse second line treatment str
Externí odkaz:
https://doaj.org/article/0a8555e1bc4d4de2ae22bfbdd71ada34
Autor:
Ondrej Fiala, Pavel Pitule, Petr Hosek, Vaclav Liska, Ondrej Sorejs, Jan Bruha, Ondrej Vycital, Tomas Buchler, Alexandr Poprach, Ondrej Topolcan, Jindrich Finek
Publikováno v:
Tumor Biology, Vol 39 (2017)
MicroRNAs regulate the expression of genes involved in several important cancer-related processes including cell adhesion, proliferation, and tumour angiogenesis. Bevacizumab is routinely used in the treatment of patients with metastatic colorectal c
Externí odkaz:
https://doaj.org/article/34c94327aacb4e9b9990be84d478dbdd
Autor:
Ondrej Fiala, Milos Pesek, Jana Skrickova, Vitezslav Kolek, Frantisek Salajka, Marcela Tomiskova, Monika Satankova, Juraj Kultan, Jana Kuliskova, Martin Svaton, Michal Hrnciarik, Karel Hejduk, Renata Chloupkova, Ondrej Topolcan, Helena Hornychova, Marketa Nova, Ales Ryska, Jindrich Finek
Publikováno v:
Tumor Biology, Vol 39 (2017)
Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still
Externí odkaz:
https://doaj.org/article/a10b69b60ee9430d88da3e92872c1cd6
Autor:
ONDREJ FIALA, PETR HOSEK, HANA KORUNKOVA, MILAN HORA, JIRI KOLAR, JINDRA WINDRICHOVA, ONDREJ SOREJS, ONDREJ TOPOLCAN, IVAN TRAVNICEK, HANA SEDLACKOVA, JINDRICH FINEK
Publikováno v:
Anticancer Research. 43:463-471
Enzalutamide (ENZ) and abiraterone acetate with prednisone (AAP) represent novel hormonal therapies used in the treatment of metastatic castration-resistant prostate cancer (mCRPC). The aim of the study was to assess the long-term outcome of mCRPC pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5f26521d747304f21587cedf5f72cdaa
https://doi.org/10.21873/anticanres.16183
https://doi.org/10.21873/anticanres.16183
Autor:
ONDREJ FIALA, JAN BAXA, MARTIN SVATON, LUCIE BENESOVA, RENATA PTACKOVA, TEREZA HALKOVA, MAREK MINARIK, PETR HOSEK, MARCELA BURESOVA, JINDRICH FINEK, JIRI FERDA, MILOS PESEK
Publikováno v:
Cancer Genomics - Proteomics. 19:270-281
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::db82bd4c2d614a36ca4d8500be6f29d4
https://doi.org/10.21873/cgp.20319
https://doi.org/10.21873/cgp.20319
Autor:
Ondrej, Fiala, Jan, Baxa, Martin, Svaton, Lucie, Benesova, Renata, Ptackova, Tereza, Halkova, Marek, Minarik, Petr, Hosek, Marcela, Buresova, Jindrich, Finek, Jiri, Ferda, Milos, Pesek
Publikováno v:
Cancer Genomics Proteomics
Background/Aim: Circulating tumour DNA (ctDNA) represents an emerging biomarker in non-small cell lung cancer (NSCLC). We focused on the combination of ctDNA and positron emission tomography/computed tomography (PET/CT) in the follow-up monitoring of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f2cdad7f836a4c8033cac0913dad5ec2
https://pubmed.ncbi.nlm.nih.gov/35181593
https://pubmed.ncbi.nlm.nih.gov/35181593
Autor:
Bohuslav Melichar, Milan Kohoutek, Lubos Petruzelka, Veronika Veskrnova, Alexandr Poprach, Tomas Buchler, Renata Chloupková, Katerina Kopeckova, Jindrich Finek, Marek Svoboda, Ladislav Dušek, Lubomír Slavíček, Igor Kiss, Ondrej Fiala
Publikováno v:
Cancer Management and Research
Tomas Buchler,1 Renata Chloupkova,2 Alexandr Poprach,3 Ondrej Fiala,4,5 Igor Kiss,3 Katerina Kopeckova,6 Ladislav Dusek,2 Veronika Veskrnova,1 Lubomir Slavicek,7 Milan Kohoutek,8 Jindrich Finek,4 Marek Svoboda,3 Lubos Petruzelka,9 Bohuslav Melichar10
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b7016cbb64a13f45e86c321245c37eab
https://doi.org/10.2147/cmar.s183093
https://doi.org/10.2147/cmar.s183093